Is semaglutide a good weight loss drug for you?

What the trial results actually show, and what they don't promise

The honest answer to whether semaglutide is a good weight loss drug starts with what the trials measured. The STEP 1 study enrolled adults with obesity or overweight plus at least one weight-related condition, without type 2 diabetes. Participants took semaglutide 2.4mg once weekly alongside lifestyle changes for 68 weeks. The average weight reduction was around 15%, meaningful by any clinical measure, and well above what diet and exercise alone typically achieve in comparable studies. You can read the original trial data on the NEJM STEP 1 paper.

That figure matters, but it is an average. Some participants lost considerably more; others lost less. If you are weighing up how good semaglutide really is against your own expectations, it helps to understand that the trial tells you what semaglutide does in a well-supported, monitored setting, it does not tell you what will happen to you personally. Results depend on adherence, tolerance, the dose reached, and the lifestyle changes made alongside treatment. Good trial data is a strong start. It is not a guarantee, and no regulated UK service should frame it as one.

It is also worth knowing that a higher maintenance dose, 7.2mg, has since received MHRA approval, with trial data showing average losses of around 20.7% over 72 weeks. That closes some of the gap with tirzepatide, the other injectable licensed for weight management in the UK. The full picture on semaglutide and weight loss is worth reading if results comparisons are a priority for you.

Who semaglutide is (and isn't) licensed for

Semaglutide for weight management is sold in the UK as Wegovy. The licensed criteria for private prescription mirror the clinical trial population fairly closely: adults aged 18 and over, with a BMI of 30 or above, or 27 or above if they have at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds may apply for certain ethnic backgrounds under UK guidance.

Semaglutide is not recommended during pregnancy, while breastfeeding, or if you are trying to conceive. It is not licensed for anyone under 18. Certain conditions (including a personal or family history of medullary thyroid carcinoma or MEN2) mean semaglutide would not be appropriate, and your prescriber will work through these with you. BMI alone is never the whole story; a clinical assessment considers your full health picture.

NICE's recommendation for semaglutide (TA875) is tied to use within a specialist weight management service for a maximum of two years. Private prescribing follows the licensed indication rather than the NICE commissioning route, but the eligibility principles are similar. If you want to understand how Wegovy sits within the broader weight loss treatment landscape, that context is useful before a consultation.

Tolerability: semaglutide's trade-off worth knowing about

Semaglutide works in part by slowing gastric emptying. That mechanism is responsible for most of the side effects people experience: nausea, vomiting, diarrhoea, constipation, indigestion, and burping are the most commonly reported. They are typically at their worst in the first few weeks and after each dose increase, then settle for most people as the body adjusts.

The dose titration schedule (starting at 0.25mg and stepping up roughly every four weeks toward the 2.4mg maintenance dose) exists precisely to manage this. Your prescriber controls the pace. Rushing titration to get faster results tends to produce more side effects, not better ones.

Less common but more serious effects include symptoms that could indicate pancreatitis: severe, persistent stomach pain that spreads to the back, with or without vomiting, needs urgent medical attention. The MHRA Yellow Card scheme allows patients to report suspected side effects and is worth bookmarking. There is also practical planning involved: Wegovy is a refrigerated medicine, so it lives in the fridge door alongside your other medicines, and rotating injection sites each week is part of the routine.

How to make the decision, and what happens next

Reading up on semaglutide as a drug, including how it works and what class of medicine it belongs to, can help you feel more confident going into a consultation. But the more useful question is whether it is right for you, at this point, given your health history, your other medicines, and your goals.

That is exactly what a clinical consultation is for. At nume, a GPhC-registered Independent Prescriber reads your answers the same day, a named clinician, not an automated filter. If you are suitable, treatment can be dispatched the same day you order before midday, arriving the next working day. If semaglutide is not the right fit, the prescriber will tell you that too, and explain why.

Before you consult, it is worth having a sense of the wider options. Exploring the treatment options available puts Wegovy in context alongside other licensed weight management medicines. And if you have specific questions about whether Wegovy is a good fit for weight loss, those are answered in detail on that page. When you are ready, check your eligibility with a free consultation, there is no obligation and no charge for the assessment itself.